Salarius Pharmaceuticals Performance
| SLRXDelisted Stock | USD 0.82 0.05 6.49% |
On a scale of 0 to 100, Salarius Pharmaceuticals holds a performance score of 4. The entity has a beta of 0.64, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Salarius Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Salarius Pharmaceuticals is expected to be smaller as well. Please check Salarius Pharmaceuticals' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to make a quick decision on whether Salarius Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Salarius Pharmaceuticals are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Salarius Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 5.9 M | |
| Free Cash Flow | -4.5 M |
Salarius |
Salarius Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 79.00 in Salarius Pharmaceuticals on November 19, 2025 and sell it today you would earn a total of 3.00 from holding Salarius Pharmaceuticals or generate 3.8% return on investment over 90 days. Salarius Pharmaceuticals is currently generating 0.4286% in daily expected returns and assumes 8.4374% risk (volatility on return distribution) over the 90 days horizon. In different words, 75% of stocks are less volatile than Salarius, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Salarius Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Salarius Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.82 | 90 days | 0.82 | about 76.98 |
Based on a normal probability distribution, the odds of Salarius Pharmaceuticals to move above the current price in 90 days from now is about 76.98 (This Salarius Pharmaceuticals probability density function shows the probability of Salarius Stock to fall within a particular range of prices over 90 days) .
Salarius Pharmaceuticals Price Density |
| Price |
Predictive Modules for Salarius Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Salarius Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Salarius Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Salarius Pharmaceuticals is not an exception. The market had few large corrections towards the Salarius Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Salarius Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Salarius Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.97 | |
β | Beta against Dow Jones | 0.64 | |
σ | Overall volatility | 1.49 | |
Ir | Information ratio | -0.19 |
Salarius Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Salarius Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Salarius Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Salarius Pharmaceuticals is now traded under the symbol DCOY. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Salarius Pharmaceuticals is not yet fully synchronised with the market data | |
| Salarius Pharmaceuticals had very high historical volatility over the last 90 days | |
| Salarius Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Salarius Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.58 M) with loss before overhead, payroll, taxes, and interest of (15.84 M). | |
| Salarius Pharmaceuticals currently holds about 22.65 M in cash with (4.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Salarius Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Salarius Stock often depends not only on the future outlook of the current and potential Salarius Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Salarius Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 64.5 K | |
| Cash And Short Term Investments | 2.4 M | |
| Shares Float | 5.8 M |
Salarius Pharmaceuticals Fundamentals Growth
Salarius Stock prices reflect investors' perceptions of the future prospects and financial health of Salarius Pharmaceuticals, and Salarius Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Salarius Stock performance.
| Return On Equity | -1.4 | |||
| Return On Asset | -0.7 | |||
| Current Valuation | 2.12 M | |||
| Shares Outstanding | 5.86 M | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 18.12 X | |||
| EBITDA | (5.73 M) | |||
| Cash And Equivalents | 22.65 M | |||
| Cash Per Share | 10.09 X | |||
| Total Debt | 221.87 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 4.50 X | |||
| Cash Flow From Operations | (4.53 M) | |||
| Earnings Per Share | (24.24) X | |||
| Total Asset | 3.02 M | |||
| Retained Earnings | (81.92 M) | |||
| Current Liabilities | 1.97 M | |||
About Salarius Pharmaceuticals Performance
Evaluating Salarius Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Salarius Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Salarius Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. Salarius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.Things to note about Salarius Pharmaceuticals performance evaluation
Checking the ongoing alerts about Salarius Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Salarius Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Salarius Pharmaceuticals is now traded under the symbol DCOY. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Salarius Pharmaceuticals is not yet fully synchronised with the market data | |
| Salarius Pharmaceuticals had very high historical volatility over the last 90 days | |
| Salarius Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Salarius Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.58 M) with loss before overhead, payroll, taxes, and interest of (15.84 M). | |
| Salarius Pharmaceuticals currently holds about 22.65 M in cash with (4.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Salarius Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Salarius Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Salarius Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Salarius Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Salarius Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Salarius Pharmaceuticals' stock. These opinions can provide insight into Salarius Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Salarius Stock
If you are still planning to invest in Salarius Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Salarius Pharmaceuticals' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |